- Home
- ARBK vs IMAB Comparison
ARBK vs IMAB Comparison
Compare ARBK & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBK
- IMAB
- Stock Information
- Founded
- ARBK 2017
- IMAB 2014
- Country
- ARBK United Kingdom
- IMAB United States
- Employees
- ARBK N/A
- IMAB N/A
- Industry
- ARBK Finance: Consumer Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ARBK Finance
- IMAB Health Care
- Exchange
- ARBK Nasdaq
- IMAB Nasdaq
- Market Cap
- ARBK 21.6M
- IMAB 384.6M
- IPO Year
- ARBK 2021
- IMAB 2020
- Fundamental
- Price
- ARBK $0.26
- IMAB $3.61
- Analyst Decision
- ARBK Hold
- IMAB Strong Buy
- Analyst Count
- ARBK 1
- IMAB 5
- Target Price
- ARBK N/A
- IMAB $6.80
- AVG Volume (30 Days)
- ARBK 872.0K
- IMAB 2.0M
- Earning Date
- ARBK 09-04-2025
- IMAB 11-02-2025
- Dividend Yield
- ARBK N/A
- IMAB N/A
- EPS Growth
- ARBK N/A
- IMAB N/A
- EPS
- ARBK N/A
- IMAB N/A
- Revenue
- ARBK $47,017,000.00
- IMAB N/A
- Revenue This Year
- ARBK $183.90
- IMAB N/A
- Revenue Next Year
- ARBK $26.78
- IMAB N/A
- P/E Ratio
- ARBK N/A
- IMAB N/A
- Revenue Growth
- ARBK N/A
- IMAB N/A
- 52 Week Low
- ARBK $0.15
- IMAB $0.60
- 52 Week High
- ARBK $1.55
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- ARBK 44.62
- IMAB 45.10
- Support Level
- ARBK $0.27
- IMAB $3.20
- Resistance Level
- ARBK $0.30
- IMAB $4.64
- Average True Range (ATR)
- ARBK 0.02
- IMAB 0.43
- MACD
- ARBK 0.00
- IMAB -0.16
- Stochastic Oscillator
- ARBK 41.83
- IMAB 24.15
About ARBK Argo Blockchain plc
Argo Blockchain PLC is a blockchain technology company focused on the large-scale mining of Bitcoin. It mines bitcoin using purpose-built computers (or mining machines) to solve complex cryptographic algorithms on the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company acquires and deploys mining technology solutions in North American facilities that utilize predominantly renewable and inexpensive electricity.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).